��������

LiverMultiScan® could be an alternative to liver biopsy for NASH clinical trials.

UVA Health First Hospital in the State to Offer LiverMultiScan for Non-Invasive Assessment of Liver Disease

�������� launches study to improve outcomes for patients with liver cancer

World’s First Integrated Imaging Service for Long Covid approved by UK’s MHRA

FDA awards funding to �������� and physicians at Massachusetts General Hospital to accelerate development of imaging biomarkers as drug development tools in liver disease

��������’s RADIcAL1 trial - addressing the health economic burden of invasive diagnostics for NAFLD and NASH

Hepatica – new tool informs surgeons about previously undiagnosed background liver disease, helping to improve surgical decision-making in liver cancer care

Post-conference Q&A - AASLD: The Digital Liver Meeting Experience

�������� presents new data, addressing key challenges of smart imaging